The prognostic relevance of BReast CAncer (BRCA) genes 1/2 mutation in advanced epithelial tubo-ovarian carcinoma and the efficacy of the Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) therapy in this group is well established [[1], [2], [3], [4], [5]]. Conversely, only limited data have been reported about the frequency and the impact, if any, of BRCA mutations in women with early-stage, high grade, serous tubo-ovarian carcinoma (HGS-eOC) [6]. This might be attributable to the relatively small population, as only about 25–30% of all epithelial ovarian cancer patients are diagnosed with International Federation of Gynecology and Obstetrics (FIGO) stage I-II [7]. Moreover, as they usually have a good prognosis, they might not derive any particular additional benefit from either the identification of prognostic factors (i.e. BRCA mutation) or further treatments, including PARPi maintenance. Nonetheless, despite a better prognosis, up 30–40% of eOC patients will relapse [6,[8], [9], [10]] and treatment algorithms are far from being individualized. In this scenario, our study aims to investigate the possible effect of BRCA status in HGS-eOC patients, with regard to both the disease's presentation at recurrence and survival outcomes.